AGEN1327 (anti-TIGIT)
Not specified
Not specifiedPipeline asset
Key Facts
About Agenus
Agenus is focused on developing novel immunotherapies designed to overcome the limitations of first-generation checkpoint inhibitors, particularly in 'cold' or immunologically resistant tumors. The company's most advanced asset, the BOT/BAL combination, has shown promising activity in multiple solid tumors and is now entering registrational studies. With a 30-year legacy in immunotherapy, Agenus leverages a multi-faceted platform to create treatments that aim to deliver deeper and more durable responses for cancer patients.
View full company profileTherapeutic Areas
Other Not specified Drugs
| Drug | Company | Phase |
|---|---|---|
| Inflammation Programs | Arcus Biosciences | Not Specified |
| Bone Marrow Conditioning Program | Telix Pharmaceuticals | Pipeline |
| AGMB-447 | Agomab Therapeutics | Not Disclosed |
| AGMB-101 | Agomab Therapeutics | Not Disclosed |
| TRIFERTY-ATM® | Laboratorio Reig Jofre | Approved/Commercial |
| AGEN1571 (anti-ILT2) | Agenus | Not specified |
| AGEN1777 | Agenus | Not specified |
| AGEN1721 | Agenus | Not specified |
| INCAGN1876 (GITR Agonist) | Agenus | Not specified |
| INCAGN1949 (OX40 Agonist) | Agenus | Not specified |
| AGEN2373 (CD137 Agonist) | Agenus | Not specified |
| AGENT-797 (iNKT Cell Therapy) | Agenus | Not specified |